Company Profiles

driven by the PitchBook Platform

pureMHC

pureMHC
2003 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
$2M LATEST DEAL AMOUNT
$2M TOTAL AMOUNT RAISED
1 INVESTORS
Description

Provider of a platform technology for disease-specific target identification. The company develops antibodies that mimic the specificity of T-cell receptors in the immune system.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
7500 Rialto Boulevard
Building 2, Suite 260
Austin, TX 78738
United States

+1 (512) 697-8167
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore pureMHC’s full profile, request a free trial.

pureMHC Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC 18-Jun-2008 $2M $2M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding request access »

pureMHC Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Texas Emerging Technology Fund Venture Capital Minority 000 0000 000000 0

pureMHC Executive Team (4)

Name Title Board
Seat
Contact
Info
Kris Looney President
Jane Yacuik Ph.D Director, Operations
William Hildebrand Ph.D Co-Founder and Chief Scientist – Target Discovery
Thomas Harlan Chief Executive Officer